The IFNGR1 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for targeted disruption of the human IFNGR1 gene. This product provides a heterogeneous pool of loss-of-function cells in which the interferon gamma receptor 1 (IFNGR1) gene is disrupted, enabling studies of IFNGR1-dependent signaling without the limitations of single-clone variability. The polyclonal format offers a robust, population-level model for functional genomics and pathway analysis in a lung adenocarcinoma context.
The host cell line, NCI-H1975, is a widely used human non-small cell lung adenocarcinoma line derived from a female nonsmoker. These cells harbor key oncogenic mutations in the epidermal growth factor receptor (EGFR) gene, specifically L858R and T790M, which confer constitutive kinase activity and are associated with acquired resistance to first-generation EGFR tyrosine kinase inhibitors. The NCI-H1975 cell line thus serves as a clinically relevant model for studying EGFR-mutant lung adenocarcinoma biology, drug resistance mechanisms, and the interplay between oncogenic signaling and other cellular pathways.
IFNGR1 encodes the ligand-binding alpha chain of the interferon gamma receptor, a critical mediator of innate and adaptive immunity. Upon binding its cognate ligand, interferon gamma (IFN-??), IFNGR1 heterodimerizes with IFNGR2, triggering activation of associated Janus kinases JAK1 and JAK2. These kinases phosphorylate signal transducer and activator of transcription 1 (STAT1), which dimerizes, translocates to the nucleus, and drives transcription of interferon-stimulated genes. Key downstream targets include the transcription factor IRF1, the feedback regulator SOCS1, as well as chemokines and major histocompatibility complex (MHC) class I and II genes. Additional signaling through STAT3 can modulate inflammatory and pro-apoptotic gene expression. Thus, IFNGR1 sits at the apex of a signaling cascade that orchestrates immune surveillance, inflammation, and cell-autonomous apoptosis.
Disruption of IFNGR1 in NCI-H1975 cells uncouples the JAK-STAT axis from IFN-?? stimulation, providing a unique tool to dissect the contribution of interferon gamma signaling to lung adenocarcinoma pathobiology. In a cellular background driven by mutant EGFR, loss of IFNGR1 may alter the balance of pro-inflammatory and anti-apoptotic signals, potentially affecting tumor cell responses to immune effectors and targeted therapies. This knockout model allows researchers to investigate how EGFR oncogenic signaling and IFN-??-mediated immune signaling intersect, shedding light on mechanisms of immune evasion, cytokine resistance, and the tumor microenvironment in lung cancer.
These polyclonal IFNGR1 knockout cells are well-suited for a wide range of experimental applications, including immune response studies, cytokine signaling analysis, JAK-STAT pathway dissection, apoptosis research, and drug resistance investigations. Representative assays include western blotting for phospho-STAT1, RT-qPCR for IRF1 transcript levels, flow cytometric quantification of MHC-I and MHC-II surface expression, and apoptosis assays following cytokine stimulation. The cells also facilitate interferon gamma signaling assays to assess pathway functionality. As an advanced gene-edited product, this knockout cell population supports mechanistic research in immunology, oncology, and inflammation. For further information or technical support, please contact Ascent Research.
